drugset / Trial / NCT04607629
An Efficacy and Safety Study of Genolar® and Xolar® in the Persistent Atopic Bronchial Asthma
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a randomized, double-blind, comparative, parallel-group study of the efficacy and safety of Genolar® and Xolair® in the treatment of persistent atopic bronchial asthma of moderate and severe course, whose symptoms are insufficiently controlled by the 4-step treatment GINA (2017)
Timeline
- Start
- 2018-06-20
- Primary completion
- 2019-04-29
- Completion
- 2019-12-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Omalizumab | Monoclonal antibody | 75 mg | Subcutaneous |
| Subject | Omalizumab | Monoclonal antibody | 600 mg | Subcutaneous |
| Background | Symbicort | Unknown | 9 ug | Inhaled |
| Background | Symbicort | Unknown | 320 ug | Inhaled |